The cardiovascular care of thousands of Missouri patients is suddenly up in the air. The heart of the issue is a practice's alleged interest in opening up a new private equity-backed clinic.
On Tuesday, a judge formally rejected a motion by the company to have the case dismissed. Carelon Behavioral Health, a subsidiary of Elevance, is accused of publishing an inaccurate directory of providers for those seeking mental health services.
Carestream Health’s recent decision to sell its healthcare information systems business to Royal Philips has been greeted with a mostly positive reaction from the imaging industry, according to a new market report.
CMS has updated its drug spending dashboards with data for 2017, adding information for “thousands” more drugs included in Medicare Parts B and D and Medicaid to its publicly accessible database.
A multitude of recent studies and success stories suggest artificial intelligence is on its way to topping doctors in accurately diagnosing diseases from asthma to breast cancer—seemingly a step in the right direction. But does the hype surrounding AI’s victories eclipse its shortcomings?
Artificial intelligence shows great promise in recognizing patterns, liberating physicians from keyboards and predicting outcomes, but where does it fall short? Medical guru Eric Topol does a deep dive into those topics and many more in his new book, Deep Medicine.
NVIDIA this week announced plans to buy chipmaker and its collaboration partner Mellanox Technologies for $6.9 billion. The move by the graphics chip giant seeks to help it push into the growing market for data center components by adding to chips that help speed the flow of information across servers.
Norman E. Sharpless, MD, director of the National Cancer Institute (NCI) since October 2017, has been announced as the new acting commissioner of the FDA. Sharpless replaces Scott Gottlieb, MD, who unexpectedly resigned from the position on March 5.
